Plunkett Research Online: CRISPR Therapeutics

CRISPR THERAPEUTICS (CRSP:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi.....



CRISPR Therapeutics
Ticker: CRSP
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 41 415613277
Fax:
Address: Baarerstrasse 14
Zug, CH-6300 Switzerland

Map
Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
Contacts Description
Samarth Kulkarni CEO/Director
Brendan Smith CFO/Chief Accounting Officer
See More
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specifi.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2021 2020 2019 2018 2017 2016
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: